CLINICAL TRIALS PROFILE FOR DOFETILIDE
✉ Email this page to a colleague
All Clinical Trials for dofetilide
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00392106 ↗ | High Intensity Focused Ultrasound (HIFU) Ablation System Study | Suspended | ProRhythm, Inc. | Phase 3 | 2006-04-01 | The purpose of this study is to determine if the HIFU Pulmonary Vein Ablation System is effective in the treatment of paroxysmal Atrial Fibrillation compared to the control of best medical therapy with FDA approved antiarrhythmic drugs. |
| NCT00657514 ↗ | Ranolazine Versus Placebo Effects on Exercise Tolerance in Patients With Heart Disease and Peripheral Arterial Disease | Withdrawn | Colorado Prevention Center | Phase 4 | 2008-05-01 | After 6 weeks of maximal Ranolazine therapy, tissue hemoglobin desaturation kinetics will change compared to placebo in patients with chronic angina and peripheral arterial disease. |
| NCT01873950 ↗ | Study of the Electrocardiographic Effects of Ranolazine, Dofetilide, Verapamil, and Quinidine in Healthy Subjects | Completed | Spaulding Clinical Research LLC | Phase 1 | 2013-05-01 | This study seeks to compare 4 known QT prolonging drugs versus placebo to determine their effects on electrophysiological and other clinical parameters. The underlying purpose is to determine if depolarization and repolarization effects caused by drugs with differing ionic channel mechanisms can be distinguished from one another, and to gauge the sensitivity and specificity of novel signal analyses for detection of depolarization and repolarization changes. Secondarily, to evaluate the exposure response relationship and drug induced effects on the heart rate biomarker relationship. |
| NCT01873950 ↗ | Study of the Electrocardiographic Effects of Ranolazine, Dofetilide, Verapamil, and Quinidine in Healthy Subjects | Completed | Food and Drug Administration (FDA) | Phase 1 | 2013-05-01 | This study seeks to compare 4 known QT prolonging drugs versus placebo to determine their effects on electrophysiological and other clinical parameters. The underlying purpose is to determine if depolarization and repolarization effects caused by drugs with differing ionic channel mechanisms can be distinguished from one another, and to gauge the sensitivity and specificity of novel signal analyses for detection of depolarization and repolarization changes. Secondarily, to evaluate the exposure response relationship and drug induced effects on the heart rate biomarker relationship. |
| NCT02308748 ↗ | Ability of Late Sodium or Calcium Current Block to Balance the ECG Effects of Potassium Current Block | Completed | Spaulding Clinical Research LLC | Phase 1 | 2014-05-01 | The primary objective of this research study is to test the hypothesis that late sodium current blocking drugs (mexiletine or lidocaine) can attenuate the effect of hERG potassium channel blocking drugs (dofetilide) on ventricular repolarization (QTc) by shortening early repolarization (J-Tpeakc). The secondary object is to assess the ability of calcium channel block (diltiazem) to reduce the QTc prolongation associated with hERG block (moxifloxacin). |
| NCT02308748 ↗ | Ability of Late Sodium or Calcium Current Block to Balance the ECG Effects of Potassium Current Block | Completed | Food and Drug Administration (FDA) | Phase 1 | 2014-05-01 | The primary objective of this research study is to test the hypothesis that late sodium current blocking drugs (mexiletine or lidocaine) can attenuate the effect of hERG potassium channel blocking drugs (dofetilide) on ventricular repolarization (QTc) by shortening early repolarization (J-Tpeakc). The secondary object is to assess the ability of calcium channel block (diltiazem) to reduce the QTc prolongation associated with hERG block (moxifloxacin). |
| NCT02365532 ↗ | Effect of Oral GS-6615 on Dofetilide-Induced QT Prolongation, Safety, and Tolerability in Healthy Adults | Completed | Gilead Sciences | Phase 1 | 2015-02-01 | This study will evaluate the effect of oral GS-6615 on QTc interval in healthy adults with dofetilide-induced QTc prolongation. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for dofetilide
Condition Name
Clinical Trial Locations for dofetilide
Trials by Country
Clinical Trial Progress for dofetilide
Clinical Trial Phase
Clinical Trial Sponsors for dofetilide
Sponsor Name
